NANOBIOTIX announced the expiration of the waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976 for its previously announced (July 10, 2023) global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV (?Janssen?), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for the investigational, potential first-in-class radioenhancer NBTXR3. With the expiration of the HSR waiting period, the transaction has become effective, and as such, Nanobiotix is eligible to receive payment of the $30 million upfront cash licensing fee.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.785 EUR | +0.37% | +9.79% | +2.18% |
May. 14 | Nanobiotix to Proceed to Phase 2 Trial of Lung Cancer Treatment | MT |
Apr. 25 | Transcript : Nanobiotix S.A., Q4 2023 Earnings Call, Apr 25, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.18% | 347M | |
+29.77% | 49.46B | |
+1.00% | 42.58B | |
+50.47% | 42.49B | |
-5.26% | 29.09B | |
+13.68% | 26.61B | |
-22.99% | 18.64B | |
+8.22% | 13.16B | |
+32.41% | 12.55B | |
-1.62% | 11.98B |
- Stock Market
- Equities
- NANO Stock
- News Nanobiotix
- NANOBIOTIX Announces Expiration of HSR Waiting Period Regarding the Agreement for Worldwide Co-Development and Commercialization of Potential First-in-Class Radioenhancer NBTXR3